Do SGLT2 inhibitors prevent atrial fibrillation in patients with cardiovascular disorders?
Patients with cardiovascular disorders, including subgroups with HFrEF and HFmrEF/HFpEF, from randomized controlled trials
SGLT2 inhibitors as a class
Control groups in randomized controlled trials
Atrial fibrillationhard clinical
SGLT2 inhibitors appear to prevent atrial fibrillation in patients with HFrEF, but this benefit is not clearly seen in those with HFmrEF or HFpEF based on trial-level meta-analysis.
Sodium-glucose co-transporter 2 inhibitors prevent AF. Their protective effect was confirmed in the HFrEF subgroup, but not in RCTs recruiting patients with HFmrEF/HFpEF, possibly indicating a different pathophysiology leading to AF among these conditions. However, given the limitations of a trial-level analysis, these findings are exploratory, pending confirmation from patient-level data.
Building similarity graph...
Analyzing shared references across papers
Loading...
Damiano Fedele
Marcello Casuso Alvarez
Angelo Maida
European Heart Journal - Cardiovascular Pharmacotherapy
University of Bologna
Azienda USL di Bologna
Ospedale G.B. Morgagni - L.Pierantoni
Building similarity graph...
Analyzing shared references across papers
Loading...
Fedele et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69de8da76bae133e7de93d34 — DOI: https://doi.org/10.1093/ehjcvp/pvaf040